Abstract
Over the past 10 years, healthcare providers involved in the management of metastatic colorectal cancer (MCRC) have seen an explosion in new agents and their combinations. These developments have resulted in an expansion in the options of care for MCRC patients and in a significant improvement in their overall survival. This article reviews the current role of anti-EGFR monoclonal antibodies in the management of MCRC and the identification of recent markers of response that lead towards treatment individualization.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab
-
Camptothecin / analogs & derivatives
-
Camptothecin / therapeutic use
-
Cetuximab
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / pathology
-
Drug Resistance, Neoplasm
-
ErbB Receptors / antagonists & inhibitors*
-
Humans
-
Irinotecan
-
Neoplasm Metastasis
-
Panitumumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Bevacizumab
-
Panitumumab
-
Irinotecan
-
ErbB Receptors
-
Cetuximab
-
Camptothecin